Huberman LabHow to Navigate Menopause & Perimenopause for Maximum Health & Vitality | Dr. Mary Claire Haver
CHAPTERS
- 5:00 – 12:00
Defining Menopause and the Problem with the Current Definition
Dr. Huberman introduces Dr. Mary Claire Haver and frames menopause as a neglected but pivotal phase for women’s health. Dr. Haver challenges the standard definition of menopause as “one year after the last period,” explaining why it excludes many women and arguing that menopause is better understood as the end of ovarian function with widespread systemic effects.
- •Current medical definition of menopause (“one year after the final menstrual period”) excludes women with hysterectomy, IUDs, ablations, PCOS, or suppressed periods.
- •Menopause as a single calendar day is less important than what it represents biologically: ovarian failure/senescence and near cessation of sex hormone production.
- •Estradiol, progesterone, and testosterone drop substantially; testosterone remains at about 50% of peak thanks to other sources.
- •Average age of menopause in the US is 51–52, with normal range 45–55.
- 12:00 – 28:10
Perimenopause Endocrinology: The ‘Zone of Chaos’
Dr. Haver walks through healthy menstrual endocrinology, then details how perimenopause begins when egg quantity and quality drop below a critical threshold. This leads to ovarian resistance to LH/FSH, erratic ovulation, huge estrogen surges, and deep troughs—creating highly volatile cycles that defy simple blood-test diagnosis.
- •Normal cycle: hypothalamus senses estradiol; GnRH → pituitary → LH/FSH pulses → ovulation → estradiol/progesterone rise and fall in regular monthly ‘EKG-like’ pattern.
- •In perimenopause (7–10 years before menopause), ovarian follicles lose sensitivity to LH/FSH; brain responds by pushing out more FSH.
- •This causes delayed or irregular ovulation, cycles that are closer or further apart, and much higher highs and lower lows of estradiol.
- •Perimenopause is best diagnosed clinically via symptoms and exclusion of other diseases; hormone labs are often misleading.
- 28:10 – 35:40
Research Gaps and Why Perimenopause Is Poorly Understood
The conversation highlights the massive underfunding and under-researching of menopause and perimenopause compared to pregnancy and other topics. Dr. Haver points to PubMed data and NIH policies to illustrate how little mechanistic work has been done on perimenopause and why this hampers evidence-based care.
- •PubMed: ~1.1 million articles on pregnancy vs. ~97,000 on menopause and ~6,400 on perimenopause.
- •Only recently has NIH required ‘sex as a biological variable’ in animal and human studies.
- •Mechanistic understanding of ovarian resistance, receptor changes, and perimenopause endocrinology is still rudimentary.
- •Despite this, observational data clearly link later menopause to better cardiometabolic outcomes due to longer estrogen exposure.
- 35:40 – 48:00
Neuropsychological Impact: Mood, Cognition, and Work
They examine how volatile hormone swings in perimenopause affect brain chemistry, leading to increased anxiety, depression, and cognitive problems often misattributed to other causes. Dr. Haver cites data on increased mental health diagnoses and job loss, and describes the emerging view that estrogen may be superior to SSRIs for many women’s perimenopausal depression.
- •At least a 40% increase in mental health disorders in perimenopause; SSRI use doubles.
- •Neurotransmitters (serotonin, norepinephrine, dopamine, GABA) are highly sensitive to estrogen, progesterone, and testosterone fluctuations.
- •Symptoms: anxiety, impaired executive function, ‘brain fog,’ word-finding issues, decreased work performance; 1 in 5 women may quit jobs due to menopause symptoms.
- •Data now show estrogen therapy in perimenopause lowers incidence of new-onset depression and can outperform SSRIs in hormone-driven mood disorders.
- 48:00 – 1:06:00
Clinical Signs, Early Menopause, and Modifiable Risk Factors
Dr. Haver lists the wide-ranging clinical manifestations of perimenopause and menopause, from abnormal bleeding to musculoskeletal pain and palpitations often mislabeled as panic attacks. She also describes early and premature menopause, associated long-term risks, and factors that can hasten or slightly delay ovarian failure.
- •Common perimenopause symptoms: dysfunctional uterine bleeding (heavy, frequent, skipped cycles), fatigue, musculoskeletal pain, palpitations, hot flashes.
- •Many conditions like fibromyalgia or irritable bladder may in some cases have been undiagnosed perimenopause/menopause.
- •Early menopause: 40–45; premature ovarian insufficiency (POI): <40. Untreated POI increases cardiovascular, diabetes, stroke, and early death risk.
- •Aggressive estrogen therapy in POI (3–4x normal menopausal doses) can restore much of the lost protection; dosing aims to approximate reproductive-age estrogen.
- •Factors that accelerate menopause: smoking, never having children (more ovulatory cycles), hysterectomy (–4 years), tubal ligation (–1.5 years), chemotherapy, inflammatory pelvic disease.
- •Genetics and maternal menopause age are major determinants; African American women tend to experience earlier menopause, Asian women somewhat later.
- 1:06:00 – 1:34:20
Birth Control, Ovulation Suppression, and Egg Freezing
They review how various contraceptives work—pill, patch, ring, hormonal and copper IUDs—and their relationships to ovulation, egg depletion, and menopause timing. The discussion dispels myths about egg harvesting reducing egg reserves and clarifies how long-term ovulation suppression slightly delays menopause.
- •Hormonal contraception (pill/patch/ring) suppresses ovulation by signaling the brain that sufficient estrogen/progestin is present.
- •IUDs work mainly by creating an inflammatory uterine environment and cervical mucus plug; levonorgestrel IUDs also thin the endometrium and can stop bleeding but usually do not suppress ovulation.
- •Long-term ovulation suppression might delay menopause by at most ~9–12 months over many years of use.
- •Egg freezing and IVF retrieval do not hasten menopause; ~11,000 follicles are lost per cycle naturally, versus ~10–12 harvested.
- •Copper IUDs do not alter ovulation and therefore do not alter menopause timing.
- 1:34:20 – 1:57:30
Nutrition, Inflammation, Visceral Fat, and the Galveston Diet
Dr. Haver emphasizes anti-inflammatory nutrition, fiber, and adequate protein as central to mitigating menopause-related inflammation and visceral fat gain. She explains how she adapted Mediterranean principles into the Galveston Diet, originally for weight loss but now focused on health, and why visceral fat is a critical target.
- •Estrogen is anti-inflammatory; its loss increases systemic inflammation, making diet, sleep, and stress reduction more important.
- •Most women consume ~10–12 g fiber/day; target is ≥25 g (benefits plateau around 30–32 g/day). Fiber supports gut microbiome, slows glucose absorption, improves bowel function.
- •Anthocyanins and a wide variety of colorful, crunchy plant foods confer diverse phytochemicals with organ-specific benefits.
- •Visceral fat rises drastically in menopause (8% → 23% of total fat), independent of weight changes, and strongly predicts chronic disease.
- •Women chronically under-consume protein (~50–60 g/day vs. needed 80–120 g/day depending on size and composition). Higher protein intake (1.5–1.7 g/kg lean mass) correlates with lower frailty.
- •Galveston Diet: Mediterranean-inspired, Americanized, anti-inflammatory plan originally built with intermittent fasting but now more focused on protein and metabolic health than on time restriction alone.
- 1:57:30 – 2:17:00
Protein, Muscle, Resistance Training, and Rethinking ‘Thin’
They delve into why muscle is the ‘organ of longevity,’ how traditional female fitness culture overemphasized leanness and cardio, and the emerging consensus around resistance training for all ages. Dr. Haver describes her late pivot from marathon running and step aerobics to heavy lifting and adequate protein, and how that informs patient advice.
- •Muscle mass controls basal metabolic rate, insulin sensitivity, and functional independence; loss accelerates after menopause.
- •Women historically exercised and ate primarily to be thin, undermining bone and muscle health.
- •New standard: resistance training 3–4x/week, heavier loads, less exclusive cardio focus.
- •Protein should be spread across meals (most women undereat protein at breakfast and overload at dinner).
- •Body composition (via DEXA/impedance or waist-to-hip ratio) is more informative than weight or BMI; WHR <0.7 is favorable, >1.0 suggests excess visceral fat.
- 2:17:00 – 2:24:20
Hot Flashes, Vasomotor Symptoms, and First-Line Treatments
The discussion turns to hot flashes and their mechanisms and management. Dr. Haver explains the thermoregulatory disruption in the hypothalamus and why systemic estrogen is the gold-standard treatment, while acknowledging ancillary tools but stressing they do not replace the root-cause fix of estrogen loss.
- •Hot flashes are vasomotor symptoms due to dysregulation of the hypothalamic thermostat, causing vasodilation, sudden heat, and sweating.
- •They can be preceded by palpitations and a wave of dysphoria; nocturnal hot flashes severely impair sleep.
- •Estrogen is the gold-standard treatment; it restores thermoregulatory stability via effects on serotonin and hypothalamus.
- •Non-hormonal interventions (e.g., some SSRIs/SNRIs, cognitive behavioral therapy, possibly turmeric) may modestly help but do not address estrogen deficiency.
- 2:24:20 – 2:48:00
The Women’s Health Initiative: What Went Wrong and Timing Matters
Dr. Haver dismantles the original interpretation of the WHI, explaining flawed design choices (age, symptom exclusion) and how relative risk increases were overhyped while absolute risks and benefits were ignored. She then outlines the ‘timing hypothesis’ and the modern, nuanced understanding of estrogen’s cardiovascular and cancer impacts.
- •WHI started women on hormone therapy at average age 63 (10–12 years post-menopause) and excluded women with hot flashes (to preserve blinding).
- •Combined estrogen-progestin arm showed a non-significant increase in breast cancer: 4→5 cases per 1,000 women/year (25% relative, ~0.1% absolute increase).
- •Estrogen-only arm (in women with hysterectomy) showed a 30% decreased breast cancer risk.
- •Press conference at the Watergate Hotel prematurely declared “estrogen causes breast cancer,” creating a global panic and 20+ years of underuse.
- •Re-analyses show that starting estrogen between 50–59 years reduces cardiovascular disease, cardiovascular death, and all-cause mortality by ~50%.
- •Estrogen is better at preventing disease than treating established atherosclerosis; adding it late may transiently loosen plaque and raise stroke risk.
- 2:48:00 – 3:07:00
Modern HRT Practice: Routes, Dosing, and Safety Considerations
Here they get practical about hormone therapy: oral vs. transdermal estrogen, role of progesterone, and tailoring doses. Dr. Haver explains why she prefers non-oral estradiol, how she titrates by symptoms rather than blood levels, and what absolute and relative contraindications look like today.
- •Oral estrogen undergoes first-pass metabolism in the liver and can raise clotting factors; transdermal routes (patch, gel, spray, vaginal ring) avoid this.
- •Women with a uterus must have a progestogen alongside systemic estrogen to prevent endometrial hyperplasia and cancer.
- •Serum estradiol levels are not well correlated with symptom relief; dosing is titrated clinically based on symptom resolution.
- •‘Bioidentical’ generally refers to molecules identical to human estradiol and progesterone; many compounded formulations are marketed without robust evidence or oversight.
- •Contraindications/precautions: unexplained abnormal uterine bleeding (must rule out cancer first), active blood clots, severe liver disease, and certain hormone-sensitive cancers (though even breast cancer survivors may sometimes use carefully selected local or systemic therapy after nuanced risk–benefit discussion).
- 3:07:00 – 3:17:00
Vaginal Estrogen, GSM, and Local Hormone Strategies
They distinguish between systemic and local hormone therapy, arguing that nearly all women should be offered vaginal estrogen for genitourinary syndrome of menopause. Dr. Haver explains how local therapies improve UTIs, incontinence, and sexual comfort, and why they’re safe even for many high-risk patients.
- •Genitourinary syndrome of menopause (GSM) arises from estrogen loss in tissues from pubic bone to sacrum, causing dryness, thinning, pain, recurrent UTIs, and bladder issues.
- •Very-low-dose vaginal estradiol or DHEA (e.g., Intrarosa) acts locally; systemic absorption is minimal and not associated with increase in systemic estrogen-related risks.
- •Vaginal estrogen is the best-established preventive treatment for recurrent UTIs in postmenopausal women and should be standard of care, especially in nursing homes.
- •Topical estriol applied to the face can reduce collagen loss and improve skin elasticity; local estrogen does not significantly elevate systemic estradiol.
- •Urogynecologists prefer patients to be ‘estroganized’ locally before and after pelvic surgeries to improve outcomes.
- 3:17:00 – 3:27:00
Testosterone, DHEA, and Female Androgen Therapy
The discussion shifts to androgens. Dr. Haver clarifies that testosterone is a critical female hormone, outlines target ranges and side effects, and describes off-label use for low libido, sarcopenia, and bone loss. She also mentions intravaginal DHEA for local estrogen/testosterone conversion.
- •Women naturally have higher absolute testosterone than estradiol; testosterone levels in healthy women are ~35–70 ng/dL.
- •Excessive levels (>90 ng/dL) can indicate tumors or PCOS; >200 ng/dL is pathologic.
- •Side effects of supraphysiologic testosterone: scalp hair loss, acne, voice deepening, increased facial/body hair.
- •No FDA-approved testosterone product for women in the US; clinicians often use lower-dose male gels or compounded creams off-label.
- •DHEA vaginal inserts (e.g., Intrarosa) are converted locally into both estradiol and testosterone, beneficial particularly for sexual function and GSM, and sometimes used even in women with breast cancer under specialist guidance.
- 3:27:00 – 3:49:00
Supplements, Bone Health, Weighted Vests, and Collagen
They cover non-hormonal tools for bone and muscle preservation: vitamin D, creatine, bioactive collagen peptides, and mechanical loading. Dr. Haver describes data on specialized collagen formulations and weighted vests for osteoporosis prevention and explains why she now thinks in 30-year horizons for her patients’ musculoskeletal health.
- •80%+ of Dr. Haver’s patients are vitamin D deficient; correcting deficiency is standard.
- •Creatine monohydrate (5 g/day) has evidence for improving muscle and bone outcomes in older women, especially when combined with resistance training.
- •Certain bioactive collagen peptides (e.g., specific German Verisol/Fortibone formulations) show improvements in bone density and skin/cellulite appearance in small but well-done trials.
- •Weighted vests (starting ~10% of body weight) improve bone density, especially in older or frail populations; loading the axial skeleton may be more beneficial than back-only loading (rucking).
- •Hip fractures in older women carry very high 1-year mortality (≈30% with surgery; ≈79% without), underscoring the importance of proactive bone health decades earlier.
- 3:49:00 – 3:59:00
GLP-1 Drugs, Weight Loss, and Menopause
They briefly explore GLP-1 agonists (Ozempic, Mounjaro, etc.) as tools for obesity and type 2 diabetes, including their potential side effects and their interaction with menopause. Dr. Haver supports cautious, well-supervised use focused on muscle preservation and long-term metabolic health, not quick cosmetic weight loss.
- •GLP-1 drugs reduce appetite and ‘food noise,’ aiding weight loss, but can also reduce muscle mass if used without attention to protein and resistance training.
- •Dr. Haver uses GLP-1s in select patients with robust counseling on protein intake, strength training, and body composition monitoring.
- •Women on HRT and GLP-1s together lose ~30% more weight than those on GLP-1s alone, suggesting synergistic metabolic effects.
- •GLP-1s can normalize ovulation in PCOS and obese women, creating ‘GLP-1 babies’; contraception counseling is critical if pregnancy is not desired.
- •Emerging evidence suggests GLP-1s may reduce other impulsive behaviors (alcohol, gambling, gaming) via reward circuitry modulation.
- 3:59:00 – 4:09:00
Mental Health Across Peri and Post-Menopause, Sleep, and Alcohol
Returning to mental health, Dr. Haver distinguishes between perimenopausal and postmenopausal psychiatric patterns. She emphasizes progesterone’s GABAergic role in sleep, the outsized impact of even modest alcohol on midlife women’s sleep, and the need to normalize hormone-based treatments for mental health in this population.
- •Perimenopause: high risk of new-onset depression/anxiety driven by hormonal volatility; estrogen often more effective than SSRIs in these cases.
- •Post-menopause: many symptoms stabilize as hormones bottom out; mental health issues may shift to more classic aging patterns.
- •Oral progesterone taken at night can improve sleep via GABA modulation; many women on combined HRT find insomnia improves significantly.
- •Alcohol tolerance drops significantly; even 1–2 drinks can cause middle-of-the-night awakenings and sweats in midlife women.
- •Non-hormonal sleep hygiene (consistent schedule, dark/cool room, limiting caffeine and screens) remains essential, but hormone support can be a powerful adjunct.
- 4:09:00 – 4:19:00
Libido, Sexual Function, and Relationship Factors
They address one of the most common listener questions: how to rekindle libido after menopause. Dr. Haver outlines the main categories of female sexual dysfunction, hormonal and non-hormonal treatments, and the central role of relationship quality alongside biology.
- •Sexual dysfunction buckets: desire (HSDD), arousal, orgasmic, pain, and relationship issues.
- •GSM-related pain is best treated with vaginal estrogen or DHEA and sometimes topical lidocaine or pelvic PT.
- •Arousal issues (blood flow) can respond to sildenafil (Viagra), including topical formulations.
- •Hypoactive sexual desire disorder (HSDD) often responds to low-dose testosterone; FDA-approved non-hormonal options include flibanserin (Addyi, daily) and bremelanotide (Vyleesi, on-demand injections).
- •Relationship quality, stress, and partner behavior are major determinants of sexual interest; biology and context must be addressed together.
- 4:19:00 – 4:28:00
How Men and Loved Ones Can Support Women Through Menopause
In response to audience questions, Dr. Haver offers guidance for male partners and family members on how to support women during these transitions. She emphasizes education, validation, shared appointments, and adjusting expectations as women navigate profound physiological and psychological changes.
- •Men should educate themselves about menopause and perimenopause using reputable sources and books, and not dismiss symptoms as ‘just stress’ or ‘aging.’
- •Validation of her experience and emotional support can mitigate feelings of isolation and self-doubt.
- •Attending medical appointments together can help with advocacy, note-taking, and decision-making about treatments including HRT.
- •Recognize that irritability, low resilience, and withdrawal may have physiological roots; approach with empathy, not blame.
- •Long-term mindset: with appropriate support, women can regain high functioning and vitality; menopause is a transition, not an endpoint.
- 4:28:00
Closing: Agency, Advocacy, and the New Menopause Mindset
The episode concludes with a focus on agency and reframing menopause as a manageable, even optimizable, life stage. Dr. Haver and Dr. Huberman highlight the need for better medical education, increased research funding, and self-advocacy, while directing listeners to Dr. Haver’s resources for further guidance.
- •Menopause and perimenopause can be navigated with high vitality using a combination of hormone therapy, lifestyle strategies, and informed care.
- •Women should expect and demand an informed discussion of HRT, not an automatic antidepressant prescription or dismissal.
- •Medical curricula and board exams currently underemphasize menopause; systemic change and legislative advocacy (NIH funding, dedicated women’s health institutes) are needed.
- •Self-tracking (symptoms, body composition, sleep) and deliberate interventions (nutrition, resistance training, sleep, minimal alcohol) are key levers of control.
- •Dr. Haver’s book, ‘The New Menopause,’ and her online content offer practical protocols; Huberman encourages continued learning and civic advocacy for better women’s health research.
